First Manhattan’s Maravai LifeSciences MRVI Stock Holding History

First Manhattan’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9	Closed	-$90	–	1522
2023 Q3	$90	Buy	+9	New	+$99	﹤0.01%	1462

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

First Manhattan's MRVI Position: Q4 2023 in Review

First Manhattan sold out of Maravai LifeSciences (MRVI) in Q4 2023, closing a stake of 9 shares — an estimated $90 sold.

First Manhattan first reported a position in MRVI in Q3 2023 and held it in 1 quarter. The position peaked at $90 in Q3 2023. 223 funds tracked by Wall St. Rank hold MRVI as of Q4 2023.

First Manhattan reported no remaining Maravai LifeSciences position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 9 Maravai LifeSciences shares in Q4 2023, an estimated $90.
First Manhattan first reported a position in Maravai LifeSciences in Q3 2023 and held it in 1 quarter.
First Manhattan's Maravai LifeSciences position peaked at $90 in Q3 2023.
223 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.